Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Dec 1;3(12):e2028484.
doi: 10.1001/jamanetworkopen.2020.28484.

Effect of Once-Weekly Azithromycin vs Placebo in Children With HIV-Associated Chronic Lung Disease: The BREATHE Randomized Clinical Trial

Rashida A Ferrand  1   2 , Grace McHugh  2 , Andrea M Rehman  3 , Hilda Mujuru  4 , Victoria Simms  2   3 , Edith D Majonga  2 , Mark P Nicol  5   6 , Trond Flaegstad  7   8 , Tore J Gutteberg  7   9 , Carmen Gonzalez-Martinez  10   11 , Elizabeth L Corbett  1   10 , Sarah L Rowland-Jones  12 , Katharina Kranzer  1   2 , Helen A Weiss  3 , Jon O Odland  7   13 ; BREATHE Trial Group
Affiliations
Randomized Controlled Trial

Effect of Once-Weekly Azithromycin vs Placebo in Children With HIV-Associated Chronic Lung Disease: The BREATHE Randomized Clinical Trial

Rashida A Ferrand et al. JAMA Netw Open. .

Abstract

Importance: HIV-associated chronic lung disease (HCLD) in children is associated with small airways disease, is common despite antiretroviral therapy (ART), and is associated with substantial morbidity. Azithromycin has antibiotic and immunomodulatory activity and may be effective in treating HCLD through reducing respiratory tract infections and inflammation.

Objective: To determine whether prophylactic azithromycin is effective in preventing worsening of lung function and in reducing acute respiratory exacerbations (AREs) in children with HCLD taking ART.

Design, setting, and participants: This double-blind, placebo-controlled, randomized clinical trial (BREATHE) was conducted between 2016 and 2019, including 12 months of follow-up, at outpatient HIV clinics in 2 public sector hospitals in Malawi and Zimbabwe. Participants were randomized 1:1 to intervention or placebo, and participants and study personnel were blinded to treatment allocation. Participants included children aged 6 to 19 years with perinatally acquired HIV and HCLD (defined as forced expiratory volume in 1 second [FEV1] z score < -1) who were taking ART for 6 months or longer. Data analysis was performed from September 2019 to April 2020.

Intervention: Once-weekly oral azithromycin with weight-based dosing, for 48 weeks.

Main outcomes and measures: All outcomes were prespecified. The primary outcome was the mean difference in FEV1 z score using intention-to-treat analysis for participants seen at end line. Secondary outcomes included AREs, all-cause hospitalizations, mortality, and weight-for-age z score.

Results: A total of 347 individuals (median [interquartile range] age, 15.3 [12.7-17.7] years; 177 boys [51.0%]) were randomized, 174 to the azithromycin group and 173 to the placebo group; 162 participants in the azithromycin group and 146 placebo group participants had a primary outcome available and were analyzed. The mean difference in FEV1 z score was 0.06 (95% CI, -0.10 to 0.21; P = .48) higher in the azithromycin group than in the placebo group, a nonsignificant difference. The rate of AREs was 12.1 events per 100 person-years in the azithromycin group and 24.7 events per 100 person-years in the placebo groups (hazard ratio, 0.50; 95% CI, 0.27 to 0.93; P = .03). The hospitalization rate was 1.3 events per 100 person-years in the azithromycin group and 7.1 events per 100 person-years in the placebo groups, but the difference was not significant (hazard ratio, 0.24; 95% CI, 0.06 to 1.07; P = .06). Three deaths occurred, all in the placebo group. The mean weight-for-age z score was 0.03 (95% CI, -0.08 to 0.14; P = .56) higher in the azithromycin group than in the placebo group, although the difference was not significant. There were no drug-related severe adverse events.

Conclusions and relevance: In this randomized clinical trial specifically addressing childhood HCLD, once-weekly azithromycin did not improve lung function or growth but was associated with reduced AREs; the number of hospitalizations was also lower in the azithromycin group but the difference was not significant. Future research should identify patient groups who would benefit most from this intervention and optimum treatment length, to maximize benefits while reducing the risk of antimicrobial resistance.

Trial registration: ClinicalTrials.gov Identifier: NCT02426112.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Nicol reported receiving grants from the National Institutes of Health (NIH) Common Fund, through the Office of Strategic Coordination/Office of the NIH Director, National Institute of Environmental Health Sciences, and National Human Genome Institute of Health during the conduct of the study. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Participant Enrollment Flowchart
AZM indicates azithromycin; and FEV1, forced expiratory volume in 1 second.
Figure 2.
Figure 2.. Cumulative Incidence of Time-to-Event Outcomes, Intention to Treat Analyses
Graphs show data for first acute respiratory exacerbation (A), all acute respiratory exacerbations (B), and all-cause hospitalizations (C). AZM indicates azithromycin.
Figure 3.
Figure 3.. Intervention Effect (Adjusted Mean Difference [AMD]) for the Primary Outcome Overall and by Subgroups
AZM indicates azithromycin; and FEV1, forced expiratory volume in 1 second.
See this image and copyright information in PMC

References

    1. Joint United Nations Programme on HIV/AIDS UNAIDS data 2019. Published December 4, 2019. Accessed November 17, 2020. https://www.unaids.org/en/resources/documents/2019/2019-UNAIDS-data
    1. Ferrand RA, Desai SR, Hopkins C, et al. . Chronic lung disease in adolescents with delayed diagnosis of vertically acquired HIV infection. Clin Infect Dis. 2012;55(1):145-152. doi:10.1093/cid/cis271 - DOI - PMC - PubMed
    1. Rylance J, Mchugh G, Metcalfe J, et al. . Chronic lung disease in HIV-infected children established on antiretroviral therapy. AIDS. 2016;30(18):2795-2803. doi:10.1097/QAD.0000000000001249 - DOI - PMC - PubMed
    1. Zar HJ. Chronic lung disease in human immunodeficiency virus (HIV) infected children. Pediatr Pulmonol. 2008;43(1):1-10. doi:10.1002/ppul.20676 - DOI - PubMed
    1. Gona P, Van Dyke RB, Williams PL, et al. . Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. 2006;296(3):292-300. doi:10.1001/jama.296.3.292 - DOI - PubMed

Publication types

MeSH terms

Associated data